MESA LABORATORIES, INC. Mesa Laboratories, Inc. Share Price
Equities
MLAB
US59064R1095
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 95.7 USD | -13.28% |
|
-14.28% | -8.66% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 212M 16.61B | Sales 2025 * | 235M 18.43B | Capitalization | 516M 40.51B |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 | Net income 2025 * | 2M 157M | EV / Sales 2024 * | 2.44 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.2 x |
| P/E ratio 2024 * |
-1,740
x | P/E ratio 2025 * |
255
x | Employees | 698 |
| Yield 2024 * |
0.67% | Yield 2025 * |
0.67% | Free-Float | 94.26% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -13.28% | ||
| 1 week | -14.28% | ||
| 1 month | -15.59% | ||
| 3 months | -12.55% | ||
| 6 months | +5.90% | ||
| Current year | -8.66% |
1 week
89.19
118.00
1 month
89.19123.79
Current year
88.65123.79
1 year
82.86145.46
3 years
82.86333.42
5 years
82.86333.42
10 years
54.60333.42
| Managers | Title | Age | Since |
|---|---|---|---|
Gary Owens
CEO | Chief Executive Officer | 56 | 19/03/17 |
John Sullivan
CHM | Chairman | 71 | 30/09/04 |
John Sakys
DFI | Director of Finance/CFO | 55 | 28/10/12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Sullivan
CHM | Chairman | 71 | 30/09/04 |
Mark Capone
BRD | Director/Board Member | 61 | 01-04 |
R. Tripeny
BRD | Director/Board Member | 65 | 22/06/22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/05/24 | 95.7 | -13.41% | 121,699 |
| 30/05/24 | 110.5 | -5.41% | 34,441 |
| 29/05/24 | 116.8 | +2.27% | 49,442 |
| 28/05/24 | 114.2 | +2.34% | 29,413 |
Delayed Quote Nasdaq, May 31, 2024 at 09:00 pm
More quotes
Mesa Laboratories, Inc. is a multinational manufacturer, developer, and seller of life sciences tools and critical quality control solutions. Its segments include Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. Its Clinical Genomics segment develops, manufactures, and sells throughput genetic analysis tools used by labs to perform clinical genomic testing in several therapeutic areas. Its Sterilization and Disinfection Control segment manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization and disinfection processes. Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Calibration Solutions segment develops, manufactures, and sells quality control products used to measure or calibrate temperature, pressure, pH, humidity, and other such parameters.
Calendar
13/06/2024
- Q4 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
95.7
USD
Average target price
130
USD
Spread / Average Target
+35.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.66% | 516M | |
| -7.16% | 178B | |
| -1.23% | 107B | |
| -4.86% | 67.04B | |
| -4.28% | 47.23B | |
| +10.32% | 44.62B | |
| +8.14% | 42.5B | |
| +15.53% | 25.22B | |
| -5.88% | 24.14B | |
| -5.38% | 23.69B |
- Stock Market
- Equities
- MLAB Stock
